Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm aims to partner for Phase III development of HMPL-004, particularly in the U.S. and Europe. "We are flexible in terms of partnerships, whether they are co-development or co-promotional in nature," CEO says..

You may also be interested in...



With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner

BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner

Hutchison MediPharma and Eli Lilly Sign New Discovery Deal

BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer

China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen

BEIJING - Shanghai-headquartered Hutchison MediPharma has frozen development of a cancer drug after Phase II clinical trials conducted in China produced inconclusive data on the efficacy of the medicine, according to company executives

Topics

UsernamePublicRestriction

Register

SC142962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel